Receive regular headline summaries whenever high-quality news is generated for this page. We'll never share your email address with others.
|11/22/2020||Georgia Cancer Center Offers Skin Cancer Screenings on Phone
... 12:01 a.m. More By TOM CORWIN, Augusta Chronicle AUGUSTA, Ga. (AP) ‚Äî Dr. Loretta Davis takes the device attached to her iPhone and presses it against a sunspot on the wrist of Dr. Jorge Cortes, the director of the Georgia Cancer Center at Augusta University. After glancing at the sharp ...
|U.S. News & World Report|
|5/29/2020||Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML | Business & Finance | manchestertimes.com
... phase CML patients who are resistant or intolerant to prior TKIs – which was demonstrated in the 45-mg followed by dose reduction to 15-mg regimen – while maintaining a manageable safety profile,” said Jorge Cortes, MD, Georgia Cancer Center at Augusta University, and an OPTIC trial principal investigator. “It is ...
|1/1/2020||UGA researcher featured in Georgia Trend
... at Georgia State University’s Institute for Biomedical Sciences, left, and Russell Allen, president and CEO of the Georgia Research Alliance Credit: jenniferstalcup.com Labor Day weekend was a bit of a blur for Dr. Jorge Cortes. As the rest of the country celebrated the end of summer, he and his family ...
|11/22/2019||Bio-Path’s Shares Dip on IND Application Approval||investingnews.com|
|11/21/2019||Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002||financialbuzz.com|
|10/28/2019||Rafael Pharmaceuticals Reaches Milestone of 25 Active Sites for Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)||Globe Newswire|
|9/16/2019||Peer-Reviewed Journal Future Oncology Publishes Two Manuscripts on Cancer Metabolism and Drug Candidate CPI-613® (Devimistat)||Globe Newswire|